Latest / Stock Movers / Deutz Buy, Astrazeneca's Trial, Computacenter Up
Transcript
- 0:02Speaker 1: Bloomberg Audio Studios, Podcasts, radio News.
- 0:08Speaker 2: The Stock Movers Report, your roundup of companies making moves
- 0:12Speaker 2: in the stock market, harnessing the power of Bloomberg Data.
- 0:16Speaker 3: Now, let's have a look out these stocks that are
- 0:18Speaker 3: on the move today here in Europe. On Caroline Hepkar
- 0:21Speaker 3: with Lizzie Burton and we joined by Bloomberg Report. To
- 0:23Speaker 3: Chloe Malay. Good morning, Chloe. Let's talk about a German company,
- 0:28Speaker 3: an engine maker, which is making a push into defense.
- 0:32Speaker 3: We just had the NATO summit, we just had the
- 0:34Speaker 3: announcement of more spending. There's a lot of focus on
- 0:37Speaker 3: this sector.
- 0:38Speaker 1: Yes, absolutely, So there's a bit of m and a
- 0:40Speaker 1: there from Deuts. So the German company Deuts, which makes
- 0:43Speaker 1: engines for buses, trucks, ships, et cetera. It is buying
- 0:47Speaker 1: the privately owned defense firm FFG for one point six
- 0:51Speaker 1: billion euros.
- 0:52Speaker 4: So FFG makes military vehicles and so.
- 0:55Speaker 1: That's the way for Deuts to expand more into this
- 0:58Speaker 1: defense sector and trying to really benefit from this rising
- 1:01Speaker 1: military spending that we've seen in Europe. And so Duds
- 1:04Speaker 1: that had already kind of been stepping up this defense push.
- 1:08Speaker 1: It had acquired stakes in you know, companies like Arx Robotics,
- 1:12Speaker 1: Titan Technologies which makes drones, and so it said that
- 1:16Speaker 1: you know, this particular deal, which is much bigger than
- 1:18Speaker 1: deals that it has done previously, would help it reach
- 1:21Speaker 1: its twenty thirty targets. Earlier, we've seen this deal making
- 1:25Speaker 1: activity pick up quite a bit in the defense sector.
- 1:28Speaker 1: Just earlier this week we had this big a deal
- 1:30Speaker 1: with Talis buying the drone summarine drone company Excel Technology.
- 1:35Speaker 1: So it looks like, you know, there's a bit of
- 1:37Speaker 1: a pick up there in terms of dealmaking activity with
- 1:40Speaker 1: the deud Steel analysts are saying that it makes sense,
- 1:43Speaker 1: although they are quite surprised by how big of a
- 1:45Speaker 1: deal this is. But overall it seems that they're quite
- 1:48Speaker 1: keen because we've seen the shares are very strongly this morning.
- 1:51Speaker 5: And Curry the biggest drag on the foot seat six.
- 1:53Speaker 5: Oh so excuse me on the six stock sectem I'm
- 1:55Speaker 5: not the foot sea today is Astrozemeka shares down nearly
- 1:58Speaker 5: ten percent. It comes to a trial for a gene
- 2:02Speaker 5: silence a drug. What's one of those when it's at home?
- 2:04Speaker 1: Yeah, So this is due to disappointing clinical trial results
- 2:09Speaker 1: for Astrasenica. And so the drug in question, it's called
- 2:12Speaker 1: when you Are it's made in a collaboration with a
- 2:15Speaker 1: company called Ionis Pharmaceutical and it's a gene silencer. So
- 2:19Speaker 1: gene silento is something that suppresses the production of abnormal
- 2:23Speaker 1: proteins in the liver. And so the trial was to
- 2:26Speaker 1: see if it could also help prevent heart problems in
- 2:29Speaker 1: patients with a rare version of heart disease. But unfortunately
- 2:33Speaker 1: when Ya did not manage to do that and to
- 2:35Speaker 1: reduce cardiovascular events or death related to heart problems. And
- 2:40Speaker 1: so that's a really big setback for Astrazenica from an
- 2:43Speaker 1: unex perspective to begin with, because the successful trial could
- 2:47Speaker 1: have led to.
- 2:47Speaker 4: Billions of dollars more in cells.
- 2:49Speaker 1: But it's also strategic setback because Astrasenica has been really
- 2:53Speaker 1: looking to establish itself in that disease area and that
- 2:57Speaker 1: particular drug in this particular trial was really a key
- 3:00Speaker 1: pillar for that. So big setback there, and as we
- 3:03Speaker 1: can see, the HIRS have taken a major hit on
- 3:05Speaker 1: the back of that.
- 3:06Speaker 3: Yeah, so that on astra Zeneca and that disappointing drug
- 3:10Speaker 3: trial issue. The IT Firm Computer Center now has managed
- 3:15Speaker 3: to switch investors on.
- 3:16Speaker 1: Yes, it has so computer Center being this IT services company,
- 3:20Speaker 1: so essentially supplying laptops to companies in the public sector
- 3:24Speaker 1: and making sure that they're working properly.
- 3:26Speaker 4: And this is apparently a great sector to be and
- 3:29Speaker 4: you know, the.
- 3:30Speaker 1: Company has had I said that it expects the four
- 3:33Speaker 1: year results to be comfortably ahead of expectations. It also
- 3:37Speaker 1: expects the first half profit to be double that of
- 3:40Speaker 1: last year, and so that is doing very very well.
- 3:44Speaker 1: And the growth driver has primarily been the US, where
- 3:48Speaker 1: it's seeing a very very strong demand from hyperscalers that
- 3:51Speaker 1: are spending a lot on all of all of that,
- 3:55Speaker 1: and today's share price boost of that was really strong,
- 3:58Speaker 1: brings THEE to day gains at fifty six percent. So
- 4:02Speaker 1: it's one of those kind of behind the scenes beneficiaries
- 4:05Speaker 1: of the AI boom, and it's doing very very well
- 4:08Speaker 1: and we are seeing that this morning.
- 4:11Speaker 2: The Stockmovers Report from Bloomberg Radio. Check back with us
- 4:15Speaker 2: throughout the day for the latest roundup of companies making
- 4:18Speaker 2: news on Wall Street and for the latest market moving headlines.
- 4:22Speaker 2: Listen to Bloomberg Radio Live, catch us on YouTube, Bloomberg
- 4:26Speaker 2: dot com, and on Applecarplay and Android Auto with the
- 4:29Speaker 2: Bloomberg Business App.